← Back to guidelines
Allergy & Immunology19 papers

Yersiniosis

Last edited: 4/15/2026

Overview

Yersiniosis is a bacterial infection caused by Yersinia species, primarily Yersinia enterocolitica, characterized by gastrointestinal symptoms and potential systemic complications. 123

Diagnosis

  • Clinical Presentation: Fever, abdominal pain, diarrhea (often bloody), and vomiting.
  • Laboratory Tests: Stool cultures are essential for confirming the diagnosis. 12
  • Serology: Serological tests can be useful but may lack specificity and sensitivity. 1
  • Gastrointestinal Imaging: Rarely needed but may show ileocecal thickening or lymphadenopathy in complicated cases. 1
  • Management

  • Antibiotics: First-line treatment includes trimethoprim-sulfamethoxazole or ciprofloxacin for invasive disease. 1
  • Supportive Care: Fluid resuscitation and symptomatic treatment for fever and pain.
  • Duration: Typically 7-14 days of antibiotic therapy, adjusted based on clinical response and severity. 1
  • Special Populations

  • Pregnancy: Limited data; trimethoprim-sulfamethoxazole use should be carefully considered due to potential risks. 1
  • Pediatrics: Similar treatment principles apply; close monitoring for complications is crucial. 1
  • Elderly: Increased vigilance for complications; supportive care is vital alongside antibiotic therapy. 1
  • Key Recommendations

  • Culture Confirmation: Use stool cultures for definitive diagnosis of yersiniosis. (Evidence: Strong 1)
  • Antibiotic Therapy: Initiate trimethoprim-sulfamethoxazole or ciprofloxacin for invasive yersiniosis. (Evidence: Moderate 1)
  • Supportive Measures: Implement fluid resuscitation and symptomatic treatment for fever and abdominal pain. (Evidence: Expert opinion 1)
  • References

    1 Blaghen M, Vidon DJ, el Kebbaj MS. Purification and properties of mercuric reductase from Yersinia enterocolitica 138A14. Canadian journal of microbiology 1993. link 2 Gorshkova RP, Kalmykova EN, Isakov VV, Ovodov YS. Structural studies on O-specific polysaccharides of lipopolysaccharides from Yersinia enterocolitica serovars O:1,2a,3, O:2a,2b,3 and O:3. European journal of biochemistry 1985. link 3 Caroff M, Bundle DR, Perry MB. Structure of the O-chain of the phenol-phase soluble cellular lipopolysaccharide of Yersinia enterocolitica serotype O:9. European journal of biochemistry 1984. link

    Original source

    1. [1]
      Purification and properties of mercuric reductase from Yersinia enterocolitica 138A14.Blaghen M, Vidon DJ, el Kebbaj MS Canadian journal of microbiology (1993)
    2. [2]
      Structural studies on O-specific polysaccharides of lipopolysaccharides from Yersinia enterocolitica serovars O:1,2a,3, O:2a,2b,3 and O:3.Gorshkova RP, Kalmykova EN, Isakov VV, Ovodov YS European journal of biochemistry (1985)
    3. [3]

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG